Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer
Junichi Hasegawa(Osaka Rosai Hospital), Masaki Mori(Tokai University), Ho Min Kim(Korea Advanced Institute of Science and Technology), Ichiro Takemasa(Osaka International University), Tsunekazu Mizushima(The University of Osaka), Yuichiro� Doki(Osaka Gakuin University), Masataka Ikeda(Hyogo Medical University), Junichi Nishimura, Yasuhiro Miyake(High Energy Accelerator Research Organization), Hirofumi Yamamoto(Osaka Gakuin University), Takeshi Kato(Osaka National Hospital), Hiroyoshi Takemoto(Kinki Central Hospital), M Sekimoto(Osaka National Hospital), Hideaki Miwa(Osaka Rosai Hospital), Hroshi Tamagawa(Osaka City General Hospital), Yujiro Fujie(The University of Osaka), Riichiro Nezu(Nishinomiya Municipal Central Hospital), Shingo Noura(Osaka Rosai Hospital), Makoto Fujii(The University of Osaka)
Cited by 87
Related Papers
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
High Incidence of Thrombosis of the Portal Venous System After Laparoscopic Splenectomy
|Annals of Surgery|2005|265
Overexpression of miR-200c Induces Chemoresistance in Esophageal Cancers Mediated Through Activation of the Akt Signaling Pathway
|Clinical Cancer Research|2011|245